{
  "docId": "019de075-60f4-719a-882e-3143e28b60e4",
  "docSlug": "fdbc224a3aaf8eece0f490c97a32599d",
  "documentTitle": "MAIA Biotechnology | Investor Presentation Deck | 35 slides",
  "authorId": "maia-biotechnology",
  "authorName": "MAIA Biotechnology",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 35,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The chart shows tumor volume over time, highlighting the superior performance of the THIO + Atezo combination compared to monotherapies and control.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-60f4-719a-882e-3143e28b60e4/18",
  "deckHref": "/decks/019de075-60f4-719a-882e-3143e28b60e4",
  "deckJsonHref": "/decks/019de075-60f4-719a-882e-3143e28b60e4.json",
  "deckAnchorHref": "/decks/019de075-60f4-719a-882e-3143e28b60e4#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.6,
        "x": 0.35,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Tumor volume over time for Control, Atezo, THIO, and THIO+Atezo groups",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1ed5821-f594-4a83-8647-cf73abd239b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.03,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "Mender et al, Cancer Cell, 2020; THIO followed by Tecentriq (atezolizumab; Roche/Genentech) tested first; repeated later with THIO followed by Keytruda (pembrolizumab; Merck); and Libtayo (cemiplimab; Regeneron)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e64d5ac3-a938-4d50-9a73-14c272fa9134",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.75,
        "y": 0.18
      },
      "kind": "legend",
      "text": "Control, Atezolizumab, THIO, THIO -> Atezo",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c5bbe331-03cc-482f-889c-7ff659bfdc66",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.35,
        "x": 0.03,
        "y": 0.2
      },
      "kind": "list",
      "text": "THIO followed by CPI results in 60% complete response; No recurrence after long-term follow-up; Anticancer immune memory has been induced: no cancer after rechallenge with 5x more lung cancer (LLC) cells with no additional therapy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb914ff2-4800-4b5b-bf1d-7d717c19d1b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "THIO-101 – RATIONALE",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ec9409b-2c1f-4d22-915e-b9d7af27d68d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Aha! Moment",
      "slug": "aha-moment",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "a7375f8e-a740-45e8-907e-9d0c319e3cb0",
      "evidence": "THIO followed by CPI results in 60% complete response; No recurrence after long-term follow-up; Anticancer immune memory has been induced: no cancer after rechallenge with 5x more lung cancer (LLC) cells",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}